Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves expanded label for Regeneron/Sanofi’s Dupixent

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc. and Sanofi SA’s drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

Sanofi and Regeneron’s Dupixent gets more positive feedback from U.S. FDA

The U.S. Food and Drug Administration accepted for priority review the license application for the use of Dupixent in adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis

Read More »

Sanofi’s eczema product Dupixent wins FDA approval to treat asthma

Sanofi SA’s eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

Read More »

Sanofi pledges to keep up restructuring efforts

Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, while several of the company’s key drugs are selling well.

Read More »

Realm Phase II Trial Fails to Reach Endpoints

Shares of Realm Therapeutics plunged more than 50 percent after the company’s Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the study.

Read More »

Galapagos, MorphoSys Ink Potential $1.1+ Billion Deal With Novartis

Galapagos and MorphoSys signed an exclusive development and commercialization deal with Novartis for a drug compound being developed for the treatment of inflammatory diseases.

Read More »

Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal

Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.

Read More »

Regeneron’s Q3 2017 profit tops Street view

Regeneron Pharmaceuticals reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for its flagship eye treatment Eylea and new eczema drug Dupixent.

Read More »

Roche unloads some rights to drug hopeful after asthma trial disappointment

Roche is offloading some rights to what was once one of its top drug prospects, lebrikizumab, for payments that could total more than $1 billion after the medicine produced only lackluster results in an asthma study during 2016.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom